Trump's order on psychedelic drugs

The order has been described as a historic moment for mental health care, potentially opening up new avenues for treating depression and PTSD. FDA Commissioner Dr. Marty Makary stated that the administration is committed to exploring innovative therapies that have shown promise in clinical trials.

However, the move has also drawn criticism from some who worry about the risks of deregulation.

The decision comes as the President faces pressure to address the growing mental health crisis in the US.